Compounding pharmacists who receive an FDA Form 483 or a warning letter face more than a correction notice. The Federal Food, Drug, and Cosmetic Act (FDCA) makes introducing an adulterated or misbranded drug into interstate commerce a federal crime, and the same inspection findings that support a warning letter can support a criminal charge. Misbranding and adulteration charges against compounding pharmacists turn on one question prosecutors ask first: was there intent to defraud or mislead, or only a documented violation.
Misdemeanor Liability Under the FDCA
21 U.S.C. § 331 prohibits introducing, delivering, or receiving in interstate commerce any drug that is adulterated or misbranded. Under 21 U.S.C. § 333(a)(1), a first violation is a misdemeanor punishable by up to one year of imprisonment, and the statute does not require the government to prove the pharmacist knew the drug was out of specification or mislabeled. That strict-liability structure means a compounding pharmacist can be convicted of a misdemeanor for a violation that happened without any intent to deceive anyone.
What Turns a Misdemeanor Into a Felony
The same statute elevates the charge to a felony in two situations: when the violation follows a prior conviction under § 333 that has become final, or when the government can show the violation was committed with intent to defraud or mislead. A felony conviction carries up to three years of imprisonment. Intent to defraud or mislead is the dividing line investigators build a case around from the first inspection: did the pharmacist know a batch was out of specification and dispense it anyway, alter records, or mislabel potency to cover a compounding error. Inspectors document that pattern before a single charge is filed.
Adulteration Theories That Start With an Inspection
An FDA inspection finding can become the factual basis for a federal adulteration charge long before any patient is harmed. 21 U.S.C. § 351 reaches a drug prepared, packed, or held under insanitary conditions where it may have been contaminated, and separately reaches a drug whose manufacturing methods, facilities, or controls do not conform to current good manufacturing practice. Both theories are built directly from what FDA investigators observe on the inspection floor: a failed air-quality reading in a sterile suite, a gap in a cleaning log, an environmental monitoring excursion that was never investigated. The Form 483 observations a pharmacist treats as a quality fix often become the charge's core exhibit.
A federal adulteration charge needs only a condition that may have allowed contamination, not proof a patient was harmed, and the government's own inspection report usually writes the case first.
Misbranding and the Compounded Drug Label
A compounded drug can be chemically correct and still be misbranded. Under 21 U.S.C. § 352, a label that is false or misleading in any particular, or that fails to carry adequate directions for use, makes the drug misbranded regardless of how carefully it was prepared. For a compounding pharmacy, exposure tracks the pharmacy's own paperwork: the formulation record, the patient-specific prescription on file, and whether the pharmacy operates as a 503A pharmacy or a 503B outsourcing facility, a distinction covered in 503A vs 503B: Which Framework Governs Your Compounding. A misbranding or adulteration inspection often runs alongside a broader federal inquiry. A compounding pharmacy under FDA scrutiny may also receive a civil investigative demand or a grand jury subpoena tied to a separate anti-kickback statute or False Claims Act theory, even though those are different statutes with different elements.
Why Early Legal Counsel Is Critical
It is critical that compounding pharmacists promptly retain experienced healthcare defense counsel upon receiving an FDA Form 483, a warning letter, or any other government inquiry. Early legal intervention can protect the pharmacist's rights, help shape appropriate responses to government requests, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with investigators on the pharmacist's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the pharmacist to unnecessary risk.
How Health Law Alliance Can Help
Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience. If your compounding pharmacy has received an FDA inspection finding, a warning letter, or a federal inquiry tied to a misbranding or adulteration theory, contact us for a free, confidential consultation through our criminal healthcare fraud defense page.
